Cargando…
Radioimmunotherapy of malignancy using antibody targeted radionuclides.
Antibodies directed against tumour associated antigens provide a means for delivering preferentially cytotoxic radionuclides to the cells of primary and secondary tumours. The factors that influence the effectiveness of the radiation in the tumour compared with its effect on the radiosensitive norma...
Autores principales: | Cobb, L. M., Humm, J. L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001604/ https://www.ncbi.nlm.nih.gov/pubmed/3542006 |
Ejemplares similares
-
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
por: Loke, Kelvin S. H., et al.
Publicado: (2011) -
Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2021) -
Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression
por: Zhang, Jiajia, et al.
Publicado: (2022) -
Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021) -
Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.
por: Bosslet, K., et al.
Publicado: (1991)